Wiener klinische Wochenschrift

, Volume 121, Issue 19–20, pp 648–660 | Cite as

Spezifische Immuntherapie bei IgE-vermittelten allergischen Erkrankungen im Kindes- und Jugendalter – eine Übersicht über in Österreich zugelassene/registrierte Allergenpräparate

Konsensus Report 2009 der AG Pneumologie und Allergologie der Österreichischen Gesellschaft für Kinder und Jugendheilkunde
  • Zsolt Szépfalusi
  • Waltraud Emminger
  • Franz Eitelberger
  • Manfred Götz
  • Andrea Grillenberger
  • Elisabeth Horak
  • Isidor Huttegger
  • Dieter Koller
  • Helmut Litscher
  • Rudolf Schmitzberger
  • Eva-Maria Varga
  • Josef Riedler
  • für die Österreichische Gesellschaft für Kinder,Jugendheilkunde
Konsensus bericht

Zusammenfassung

Der Consensus Report zur Spezifischen Immuntherapie bei IgE-vermittelten allergischen Erkrankungen im Kindes- und Jugendalter ist einerseits aufgrund des zunehmend größeren Angebotes an Allergenpräparaten entstanden. Andererseits besteht die ethische Verpflichtung Kinder und Jugendliche mit Allergenpräparaten zu behandeln, die auch in Studien an Kindern und Jugendlichen getestet worden sind (EU Regulative). Neben einer Auflistung aller in Österreich für den Gebrauch an Kindern zugelassener Allergenpräparate folgt eine differenzierte und kritische Betrachtung der Studienlandschaft. Neue Studien an Kindern sind zu fordern, gleichzeitig ist auch ein deutlicher Nachholbedarf in der Anwendung dieser sehr effektiven Behandlungsform IgE-vermittelter Allergien festzuhalten.

Schlüsselwörter

Immuntherapie Allergie Kinder Jugendliche 

Allergen-specific Immunotherapy for children and adolescents – a review on available products in Austria

Summary

A pediatric consensus report on allergen-specific immunotherapy for children and adolescents is presented for Austria. Products on the market in Austria are presented and categorised according to studies performed on the target population of children and adolescents, their effectiveness and indication. In general, more clinical studies on children and adolescents are mandatory for most of the available allergen-specific immunotherapeutics. In addition, the use of allergen-specific immunotherapy in general should be promoted as the exclusive treatment with long-lasting effects in type I allergies in particular in children.

Keywords

Immunotherapy Allergy Children Adolescents 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referenzen

  1. Coifman RE, Cox LS (2006) American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns. J Allergy Clin Immunol 2007 119: 1012–1013CrossRefGoogle Scholar
  2. Madsen F (2007) EAACI 'Standards for practical allergen-specific immunotherapy'. Allergy 62: 332PubMedCrossRefGoogle Scholar
  3. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al (2007) Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62: 317–324PubMedCrossRefGoogle Scholar
  4. Malling HJ (1999) WHO position paper (summary) – allergen-immunotherapy: therapeutic vaccines for allergic diseases. Wien Med Wochenschr 149: 410–414PubMedGoogle Scholar
  5. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, et al (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81: 401–405PubMedGoogle Scholar
  6. Wilson DR, Lima MT, Durham SR (2005) Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60: 4–12PubMedCrossRefGoogle Scholar
  7. Passalacqua G, Durham SR (2007) Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 119: 881–891PubMedCrossRefGoogle Scholar
  8. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S (2007) Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev CD001936Google Scholar
  9. Abramson MJ, Puy RM, Weiner JM (2003) Allergen immunotherapy for asthma. Cochrane Database Syst Rev CD001186Google Scholar
  10. Kleine-Tebbe J, Bergmann KC, Friedrichs F, Fuchs T, Jung K, Klimek L, et al (2006) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 15: 56–74Google Scholar
  11. Regulation of (EC) No 1901/2006 the Euopean Parliament and of the Council of December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol1/reg_2006_1901/reg_2006_1901_en.pdf
  12. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW (2009) Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 102: 22–28PubMedGoogle Scholar
  13. Akdis M, Akdis CA (2007 Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119: 780–791PubMedCrossRefGoogle Scholar
  14. Larche M, Akdis CA, Valenta R(2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6: 761–771PubMedCrossRefGoogle Scholar
  15. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J(1997) Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27: 1131–1139PubMedCrossRefGoogle Scholar
  16. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR (1995) Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154: 4187–4194PubMedGoogle Scholar
  17. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT(1993) Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178: 2123–2130PubMedCrossRefGoogle Scholar
  18. Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH, Hawrylowicz CM (2003) Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin Exp Allergy 33: 1209–1215PubMedCrossRefGoogle Scholar
  19. Till S, Walker S, Dickason R, Huston D, O'Brien F, Lamb J, et al (1997) IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 110: 114–121PubMedCrossRefGoogle Scholar
  20. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, et al (2002) Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 105: 56–62PubMedCrossRefGoogle Scholar
  21. Francis JN, Till SJ, Durham SR (2003) Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111: 1255–1261PubMedCrossRefGoogle Scholar
  22. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K (1998) Role of interleukin 10 in specific immunotherapy. J Clin Invest 102: 98–106PubMedCrossRefGoogle Scholar
  23. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al (2003) IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33: 1205–1214PubMedCrossRefGoogle Scholar
  24. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al (2004) Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172: 3252–3259PubMedGoogle Scholar
  25. Savolainen J, Jacobsen L, Valovirta E (2006) Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61: 1184–1190PubMedCrossRefGoogle Scholar
  26. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al (2004) Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363: 608–615PubMedCrossRefGoogle Scholar
  27. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al (2004) Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199: 1567–1575PubMedCrossRefGoogle Scholar
  28. Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C, Francis JN, et al (2007) Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 119: 937–943PubMedCrossRefGoogle Scholar
  29. Bohle B (2007) The impact of pollen-related food allergens on pollen allergy. Allergy 62: 3–10PubMedCrossRefGoogle Scholar
  30. Evans R, Pence H, Kaplan H, Rocklin RE (1976) The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest 57: 1378–1385PubMedCrossRefGoogle Scholar
  31. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, et al (1998) Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 101: 506–513PubMedCrossRefGoogle Scholar
  32. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al (1998) Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101: 747–754PubMedCrossRefGoogle Scholar
  33. Wachholz PA, Soni NK, Till SJ, Durham SR (2003) Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 112: 915–922PubMedCrossRefGoogle Scholar
  34. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW (1982) Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 70: 261–271PubMedCrossRefGoogle Scholar
  35. van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Wurtzen PA (2004) A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 34: 420–428PubMedCrossRefGoogle Scholar
  36. Löwer J, Becker W-M, Vieths S (2003) Regulatory control and standardization of allergenic extracts. Frankfurt/ Main: Druck- und Verlagshaus Sperlich. Arb Paul Ehrlich Inst. Bundesamt Sera Impfstoffe, 65–115Google Scholar
  37. Kleine-Tebbe J, Fuchs T, Klimek L, Kuhr J, Lepp U, Niggemann B, et al (2001) Allergen immunotherapy – a position paper of the German society for allergology and clinical immunology. Pneumologie 55: 438–444PubMedCrossRefGoogle Scholar
  38. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G (1999) Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 54: 313–319PubMedCrossRefGoogle Scholar
  39. Brewczynski PZ, Kroon AM (1999) Wirksamkeit und Verträglichkeit einer Immuntherapie mit modifizierten Gräserpollenallergenen. Allergologie 22: 411–420Google Scholar
  40. Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR (2003) Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MLP) for children and adolecents. Allergol et Immunopathol 31: 270–277CrossRefGoogle Scholar
  41. Drachenberg KJ, Pfeiffer P, Urban E (2001) Sublinguale Immuntherapie. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie mit einem standardisierten Birken- und Gräser-/Roggenpollenextrakt. Allergologie 24: 525–534Google Scholar
  42. Zielen S, Metz D, Sommer E, Scherf H-P (2007) Kurzzeit-Immuntherapie mit Allergoiden und dem Adjuvans Monophosphoryl-Lipid-A. Allergologie 30: S1–S8Google Scholar
  43. Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O (2006) The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 17: 396–407PubMedCrossRefGoogle Scholar
  44. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP (2006) Twelve-year follow-up after discontinuation of pre-seasonal grass pollen immunotherapy in childhood. Allergy 61: 198–201PubMedCrossRefGoogle Scholar
  45. Eng PA, Reinhold M, Gnehm HP (2002) Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 57: 306–312PubMedCrossRefGoogle Scholar
  46. Businco L, Zannino L, Cantani A, Corrias A, Fiocchi A, La Rosa M (1995) Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatr Allergy Immunol 6: 44–47PubMedCrossRefGoogle Scholar
  47. Bousquet J, Lockey R, Malling HJ (2001) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558–562CrossRefGoogle Scholar
  48. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108: S147–334Google Scholar
  49. Eng P, Gnehm HE, Joller-Jemelka HI (1994) Clinical and immunologenic effects of preseasonal hyposenitization in children with pollinosis. Monatsschr Kinderheilkd 142: 616–622Google Scholar
  50. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109: 251–256PubMedCrossRefGoogle Scholar
  51. Fontana V, Holt LJ, Mainland D (1966) Effectiveness of hyposensitization therapy in ragweed hay-fever in children. JAMA 195: 985–992PubMedCrossRefGoogle Scholar
  52. Weisnagel J (1979) Nouvel agent hyposensibilisant dans le traitement de la rhinite allergique saisonniere (fievre des foins) a l'herbe a poux chez lnfant: le MRTA (modified rag weed tyrosine adsorbate). Union Med Can 108: 685–690PubMedGoogle Scholar
  53. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S (1986) A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 41: 131–140PubMedCrossRefGoogle Scholar
  54. Roder E, Berger MY, de Groot H, van Wijk RG (2008) Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 19: 197–207PubMedCrossRefGoogle Scholar
  55. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al (2007) Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62: 943–948PubMedCrossRefGoogle Scholar
  56. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al (2004) Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114: 851–857PubMedCrossRefGoogle Scholar
  57. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, et al (2004) Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 59: 491–497PubMedCrossRefGoogle Scholar
  58. Mortemousque B, Bertel F, De Casamayor J, Verin P, Colin J (2003) House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 33: 464–469PubMedCrossRefGoogle Scholar
  59. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al (2003) Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33: 206–210PubMedCrossRefGoogle Scholar
  60. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, et al (2004) The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 59: 973–979PubMedCrossRefGoogle Scholar
  61. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P, et al (2002) Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 129: 248–253PubMedCrossRefGoogle Scholar
  62. Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S, et al (1999) Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54: 819–828PubMedCrossRefGoogle Scholar
  63. Clavel R, Bousquet J, Andre C (1998) Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53: 493–498PubMedCrossRefGoogle Scholar
  64. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H (1994) A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 49: 309–313PubMedCrossRefGoogle Scholar
  65. Bahceciler NN, Isik U, Barlan IB, Basaran MM (2001) Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 32: 49–55PubMedCrossRefGoogle Scholar
  66. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW (1999) Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 104: 425–432PubMedCrossRefGoogle Scholar
  67. Ullrich D, Thum-Oltimer S, Mussler S, Jaeschke B (2007) Successful specific subcutaneous immunotherapy (SCIT) with non-modified semi-depot pollen and mite preparations. Allergo J 2007: 193–198Google Scholar
  68. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C, et al (1998) Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53: 662–672PubMedCrossRefGoogle Scholar
  69. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y (2007) Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 17: 85–91PubMedGoogle Scholar
  70. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M (1996) A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 51: 489–500PubMedGoogle Scholar
  71. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S (2001) Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31: 1392–1397PubMedCrossRefGoogle Scholar
  72. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al (2005) Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 35: 560–564PubMedCrossRefGoogle Scholar
  73. Marcucci F, Sensi L, Frati F, Bernardini R, Novembre E, Barbato A, et al (2003) Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 58: 657–662PubMedCrossRefGoogle Scholar
  74. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J (2006) Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 61: 1177–1183PubMedCrossRefGoogle Scholar
  75. Bordignon V, Parmiani S (2003) Variation of the skin endpoint in patients treated with sublingual specific immunotherapy. J Investig Allergol Clin Immunol 13: 170–176PubMedGoogle Scholar
  76. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP (1995) Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 23: 224–230Google Scholar
  77. Passalacqua G, Musarra A, Pecora S, Amoroso S, Antonicelli L, Cadario G, et al (2007) Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 18: 58–62PubMedCrossRefGoogle Scholar
  78. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G (2003) Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 33: 1641–1647PubMedCrossRefGoogle Scholar
  79. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, et al (2003) Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 14: 216–221PubMedCrossRefGoogle Scholar
  80. Tari MG, Mancino M, Monti G (1990) Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 18: 277–284Google Scholar
  81. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al (2009) Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123: 167–173 e7PubMedCrossRefGoogle Scholar
  82. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI (2006) Once daily sublingual immunotherapy without updosing--A new treatment schedule. Int Arch Allergy Immunol 140: 321–326PubMedCrossRefGoogle Scholar
  83. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F (2005) Dose dependence of immunological response to sublingual immunotherapy. Allergy 60: 952–956PubMedCrossRefGoogle Scholar
  84. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al (2009) Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 123: 160–166 e3PubMedCrossRefGoogle Scholar
  85. Bergmann KC (2003) [Specific immunotherapy in allergic asthma]. Pneumologie 57: 84–90PubMedCrossRefGoogle Scholar
  86. Gillissen A, Bergmann KC, Kleine-Tebbe J, Schultze-Werninghaus G, Virchow JC Jr, Wahn U, et al (2003) Specific immunotherapy in allergic asthma. Dtsch Med Wochenschr 128: 204–209PubMedCrossRefGoogle Scholar
  87. Bousquet J (1999) Specific immunotherapy in asthma. Allergy 54 [Suppl 56]: 37–38PubMedCrossRefGoogle Scholar
  88. Bousquet J, Michel FB, Malling HJ (1995) Is allergen immunotherapy effective in asthma? A meta-analysis of randomized clinical trials. Am J Respir Crit Care Med 152: 1737–1738PubMedGoogle Scholar
  89. Calamita Z, Saconato H, Pela AB, Atallah AN (2006) Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 61: 1162–1172PubMedCrossRefGoogle Scholar
  90. Giovane AL, Bardare M, Passalacqua G, Ruffoni S, Scordamaglia A, Ghezzi E, et al (1994) A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 24: 53–59PubMedCrossRefGoogle Scholar
  91. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C, et al (1995) Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 96: 879–885PubMedCrossRefGoogle Scholar
  92. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, et al (1991) Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 87: 955–964PubMedCrossRefGoogle Scholar
  93. Bertelsen A, Andersen JB, Christensen J, Ingemann L, Kristensen T, Ostergaard PA (1989) Immunotherapy with dog and cat extracts in children. Allergy 44: 330–335PubMedCrossRefGoogle Scholar
  94. Roberts G, Hurley C, Turcanu V, Lack G (2006) Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 117: 263–268PubMedCrossRefGoogle Scholar
  95. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, et al (2006) A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 61: 191–197PubMedCrossRefGoogle Scholar
  96. Zimmermann T, Meyer-Ehmsen K (1988) Diagnostik und Therapie der Sensibilisierung gegen Dermatophagoides pteronyssinus und Dermatophagoides farinae bei Kindern. Allergologie 11: 503–508Google Scholar
  97. Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L (1986) Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 57: 173–179PubMedGoogle Scholar
  98. Sundin B, Lilja G, Graff-Lonnevig V, Hedlin G, Heilborn H, Norrlind K, et al (1986) Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 77: 478–487PubMedCrossRefGoogle Scholar
  99. Cevit O, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB (2007) Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children. J Investig Allergol Clin Immunol 17: 286–291PubMedGoogle Scholar
  100. Shim JY, Kim BS, Cho SH, Min KU, Hong SJ (2003) Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 33: 52–57PubMedCrossRefGoogle Scholar
  101. Pajno GB, Morabito L, Barberio G, Parmiani S (2000) Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 55: 842–849PubMedCrossRefGoogle Scholar
  102. Pajno GB, Passalacqua G, Vita D, Caminiti L, Parmiani S, Barberio G (2004) Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 59: 883–887PubMedCrossRefGoogle Scholar
  103. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J (1997) Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99: 450–453PubMedCrossRefGoogle Scholar
  104. Reha CM, Ebru A (2007) Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 35: 44–51CrossRefGoogle Scholar
  105. Purello-D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, et al (2001) Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31: 1295–1302PubMedCrossRefGoogle Scholar
  106. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, et al (2003) Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 16: 73–79PubMedGoogle Scholar
  107. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM (2004) Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 351: 668–674PubMedCrossRefGoogle Scholar
  108. Schafer T, Ring J (1997) Epidemiology of allergic diseases. Allergy 52: 14–22; discussion 35–36PubMedCrossRefGoogle Scholar
  109. Menardo JL, Bousquet J, Ville G, Michel FB (1983) Desensitisation with hymenoptera venom in children. Arch Fr Pediatr 40: 543–547PubMedGoogle Scholar
  110. Urbanek R, Forster J, Kuhn W, Ziupa J (1985) Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 107: 367–371PubMedCrossRefGoogle Scholar
  111. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, et al (1990) The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 323: 1601–1603PubMedCrossRefGoogle Scholar
  112. Steiss JO, Jodicke B, Lindemann H (2006) A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc 27: 148–150PubMedGoogle Scholar
  113. Laurent J, Smiejan JM, Bloch-Morot E, Herman D (1997) Safety of Hymenoptera venom rush immunotherapy. Allergy 52: 94–96PubMedCrossRefGoogle Scholar
  114. Schuetze GE, Forster J, Hauk PJ, Friedl K, Kuehr J (2002) Bee-venom allergy in children: long-term predictive value of standardized challenge tests. Pediatr Allergy Immunol 13: 18–23PubMedCrossRefGoogle Scholar
  115. Przybilla B, Rueff F (1999) [Desensitization of allergy to hymenoptera venoms]. Wien Med Wochenschr 149: 421–428PubMedGoogle Scholar
  116. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R (2003) Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 58: 1176–1179PubMedCrossRefGoogle Scholar
  117. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al (2007) Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 120: 164–170PubMedCrossRefGoogle Scholar
  118. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61: 202–205PubMedCrossRefGoogle Scholar
  119. Leroy B, Lachapelle JM, Jacquemin MG, Saint-Remy JM (1993) Immunotherapy of atopic dermatitis by injections of antigen-antibody complexes. Dermatology 186: 276–277PubMedCrossRefGoogle Scholar
  120. Ring J (1982) Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 107: 597–602PubMedCrossRefGoogle Scholar
  121. Warner JO, Price JF, Soothill JF, Hey EN (1978) Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 2: 912–915PubMedCrossRefGoogle Scholar
  122. Glover MT, Atherton DJ (1992) A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 22: 440–446PubMedCrossRefGoogle Scholar
  123. Cadario G, Galluccio AG, Pezza M, Appino A, Milani M, Pecora S, et al (2007) Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin 23: 2503–2506PubMedCrossRefGoogle Scholar
  124. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G, et al (2000) Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr) 28: 54–62Google Scholar
  125. Werfel T, Aberer W, Augustin M, Biedermann T, Fölster-Holst R, Friedrichs F, et al (2008) Leitlinien: Neurodermitis. AWMW online 2008Google Scholar
  126. Potter PC (2006) Update on sublingual immunotherapy. Ann Allergy Asthma Immunol 96: S22–S25PubMedCrossRefGoogle Scholar
  127. Wilson DR, Torres LI, Durham SR (2003) Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003: CD002893Google Scholar
  128. Pajno GB (2007) Sublingual immunotherapy: the optimism and the issues. J Allergy Clin Immunol 119: 796–801PubMedCrossRefGoogle Scholar
  129. Passalacqua G, Guerra L, Pasquali M, Canonica GW (2006) Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets 5: 43–51PubMedCrossRefGoogle Scholar
  130. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al (2006) Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 97: 141–148PubMedCrossRefGoogle Scholar
  131. Roder E, Berger MY, de Groot H, Gerth van Wijk R (2008) Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 38: 1659–1667PubMedCrossRefGoogle Scholar
  132. Pajno GB, Vita D, Caminiti L, Arrigo T, Lombardo F, Incorvaia C, et al (2005) Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 116: 1380–1381PubMedCrossRefGoogle Scholar
  133. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U (2005) Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 60: 1459–1470PubMedCrossRefGoogle Scholar
  134. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ (1996) Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 97: 1207–1213PubMedCrossRefGoogle Scholar
  135. Jarisch R, Gotz M, Aberer W, Sidl R, Stabel A, Zajc J, et al (1988) Reduction of side effects of specific immunotherapy by premedication with antihistaminics and reduction of maximal dosage to 50.000 SQ-U/ml. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, pp163–175Google Scholar
  136. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J (1997) Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 100: 458–463PubMedCrossRefGoogle Scholar
  137. Reimers A, Hari Y, Muller U (2000) Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55: 484–488PubMedCrossRefGoogle Scholar
  138. Muller UR, Jutel M, Reimers A, Zumkehr J, Huber C, Kriegel C, et al (2008) Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 122: 1001–1007 e4PubMedCrossRefGoogle Scholar
  139. Malling HJ (2000) Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 23: 323–332PubMedCrossRefGoogle Scholar
  140. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D (2001) Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz 44: 709–718Google Scholar
  141. Simons FE (2004) First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 113: 837–844PubMedGoogle Scholar
  142. Simons FE, Gu X, Johnston LM, Simons KJ (2000) Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics 106: 1040–1044PubMedCrossRefGoogle Scholar
  143. Sheikh A, Shehata YA, Brown SG, Simons FE (2009) Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy 64: 204–212PubMedCrossRefGoogle Scholar
  144. Simons FE (2003) H1-Antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol 112: S42–52PubMedCrossRefGoogle Scholar
  145. Sampson HA, Munoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al (2005) Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 115: 584–591PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Zsolt Szépfalusi
    • 1
  • Waltraud Emminger
    • 2
  • Franz Eitelberger
    • 3
  • Manfred Götz
    • 4
  • Andrea Grillenberger
    • 5
  • Elisabeth Horak
    • 6
  • Isidor Huttegger
    • 7
  • Dieter Koller
    • 1
  • Helmut Litscher
    • 8
  • Rudolf Schmitzberger
    • 9
  • Eva-Maria Varga
    • 10
  • Josef Riedler
    • 11
  • für die Österreichische Gesellschaft für Kinder,Jugendheilkunde
  1. 1.Univ.-Klinik für Kinder und JugendheilkundeAustria
  2. 2.Allergieambulatorium RennwegWienAustria
  3. 3.Abteilung für Kinder- und Jugendheilkunde im Klinikum Wels – GrieskirchenAustria
  4. 4.Floridsdorfer AllergiezentrumWienAustria
  5. 5.Abteilung für Kinder- und JugendheilkundeLandeskinderklinik LinzLinzAustria
  6. 6.Univ.-Klinik für Kinder und JugendheilkundeInnsbruckAustria
  7. 7.Univ.-Klinik für Kinder- und JugendheilkundeParacelsus Medizinische PrivatuniversitätAustria
  8. 8.LKH-KlagenfurtAbteilung für Kinder- und JugendheilkundeKlagenfurtAustria
  9. 9.Facharzt für Kinder und JugendheilkundeWienAustria
  10. 10.Univ.-Klinik für Kinder und JugendheilkundeKlinische Abteilung für Pulmonologie und AllergologieGrazAustria
  11. 11.Abteilung für Kinder und Jugendheilkunde, Kardinal Schwarzenberg'sches KrankenhausLeiter der AG Pneumologie und Allergologie der Österreichischen Gesellschaft für Kinder und JugendheilkundeAustria

Personalised recommendations